Predictive Oncology Inc. (POAI): history, ownership, mission, how it works & makes money

A Brief History of Predictive Oncology Inc. (POAI)

Company Formation and Background

Predictive Oncology Inc. (POAI) was established with a vision to revolutionize cancer treatment and prediction through advanced data analytics and personalized medicine. The company emerged from a merger involving Cancer Genetics, Inc. and Skyline Medical Holdings, signed in 2020, culminating in a focus on using artificial intelligence and machine learning to analyze cancer data.

Initial Public Offerings and Market Performance

POAI went public on NASDAQ in 2018. The initial public offering (IPO) was approximately $5.00 per share. As of October 2023, the stock was trading around $0.80 per share, reflecting significant volatility and challenges in the biotechnology sector.

Key Financial Data

For the fiscal year ended December 31, 2022, Predictive Oncology reported total revenue of approximately $1.2 million, a slight increase from about $1.1 million in 2021. However, the company faced a net loss of $6.1 million for 2022, down from a net loss of $5.4 million in 2021.

Strategic Partnerships and Collaborations

In 2021, Predictive Oncology announced collaborations with several research institutions, including a partnership with the University of Minnesota to advance its oncology pipeline and data analytics. Such collaborations aimed to enhance predictive modeling capabilities.

Technological Innovations

POAI has developed several proprietary technologies, such as the Tissue of Origin assay, which utilizes machine learning algorithms for better cancer stratification and therapy predictions. The company focuses on expanding its AI-driven platforms to improve treatment outcomes and patient management.

Market Capitalization and Investment Considerations

As of October 2023, the market capitalization of Predictive Oncology stood at approximately $37 million, reflecting the current economic environment and investor sentiment toward biotech firms. The volatility of its stock price necessitates cautious investment considerations from potential stakeholders.

Recent Developments

In 2023, POAI announced the launch of several new studies aimed at further validating its predictive models. The company has focused on expanding its clinical trial footprint and enhancing its database to improve accuracy in cancer predictions.

A Who Owns Predictive Oncology Inc. (POAI)

Major Shareholders

Predictive Oncology Inc. (POAI) has a variety of shareholders ranging from institutional investors to individual stakeholders. As of the latest filings, the following table represents the major shareholders of the company:

Insider Ownership

Insider ownership is a significant factor in understanding the governance of Predictive Oncology Inc. The following table outlines the key executives and their respective ownership stakes:

Institutional Investment Trends

Institutional investment has been a key aspect of POAI's stock performance. The following statistics illustrate the recent trends:

• Latest market capitalization: $55 million
• Current stock price (as of October 2023): $1.10 per share
• Recent trading volume: 150,000 shares per day
• Average analyst rating: 2.50 (on a scale of 1 to 5)

Recent Developments

Recent announcements regarding new partnerships and collaborations have affected ownership structures:

• Partnership with a leading pharmaceutical company in Q3 2023.
• Funding round completed with $10 million raised in September 2023.
• Increased retail investor interest noted after Q2 earnings report.

Conclusion on Ownership Dynamics

The ownership structure of Predictive Oncology Inc. is a mix of institutional investors, individual insiders, and retail investors, shaping the company's strategic direction and market potential.

Predictive Oncology Inc. (POAI) Mission Statement

Company Overview

Predictive Oncology Inc. (POAI) is focused on advancing the field of personalized medicine through the development of innovative cancer treatment strategies. The company aims to enhance patient outcomes by utilizing artificial intelligence and machine learning to analyze vast datasets related to tumor biology and treatment responses.

Mission Statement

POAI's mission is to improve cancer treatment and patient quality of life through transformative precision medicine solutions, driven by cutting-edge technology and comprehensive data analysis.

Core Values

• Innovation: Continuously seeking groundbreaking solutions.
• Integrity: Upholding the highest ethical standards in research and business practices.
• Collaboration: Partnering with healthcare professionals, researchers, and stakeholders.
• Patient-Centricity: Focusing on improving patient outcomes and experiences.

Market Position

As of Q3 2023, Predictive Oncology has positioned itself as a key player in the oncology market, which is projected to reach $200 billion by 2026, growing at a CAGR of 7.8%.

Financial Performance

In the fiscal year 2022, Predictive Oncology reported revenues of $6.8 million, a significant increase from $3.1 million in 2021. The company posted a net loss of $9.2 million for 2022 compared to a net loss of $6.5 million in the previous year.

Investment and Funding

Predictive Oncology has secured funding totaling $28 million from various investors, including private placements and public offerings.

Key Offerings

Collaboration and Partnerships

POAI collaborates with leading medical institutions and pharmaceutical companies to enhance its research capabilities and expand the reach of its innovative solutions. As of 2023, it has formed partnerships with over 25 research institutions.

Conclusion on Alignment with Mission

Through its innovative products, strategic partnerships, and financial growth, Predictive Oncology Inc. is committed to fulfilling its mission of transforming cancer treatment, thereby significantly impacting the lives of patients facing this challenging disease.

How Predictive Oncology Inc. (POAI) Works

Business Model

Predictive Oncology Inc. operates primarily in the healthcare sector, focusing on the development of personalized cancer treatments through predictive modeling. The company utilizes its proprietary platform to analyze and interpret vast datasets related to tumor biology.

Key Services

• Predictive Analytics: The company employs advanced algorithms and machine learning techniques to predict patient responses to various cancer therapies.
• Biomarker Discovery: Identifying potential biomarkers that can indicate the effectiveness of treatments.
• Clinical Trials Support: Providing services to pharmaceutical and biotech companies for clinical trial design and execution.

Financial Overview

As of Q2 2023, Predictive Oncology reported revenues totaling approximately $4.1 million, marking a year-over-year increase of 15% from the previous year.

The company’s operating expenses for the same quarter were around $5.8 million, leading to a net loss of $1.7 million.

Technology Utilization

POAI utilizes a unique technology platform, focusing on the integration of genomic data and artificial intelligence. This combination enables the identification of optimal treatment plans tailored to individual patient profiles.

Target Market

The primary market for Predictive Oncology includes oncology centers, pharmaceutical companies, and research institutions focusing on cancer treatment innovations. As of 2023, the global oncology market was valued at approximately $200 billion, with projections to grow at a CAGR of 7.4% through 2028.

Partnerships and Collaborations

• Collaboration with Academic Institutions: Partnering with leading universities for research and development.
• Alliances with Pharmaceutical Companies: Engaging in joint ventures to develop new therapies.

Research and Development

Predictive Oncology emphasizes R&D, with approximately $2 million allocated for research initiatives in 2023. This investment focuses on enhancing predictive analytic capabilities and expanding biomarker discovery efforts.

Regulatory Landscape

POAI operates under stringent regulations set forth by the FDA and other health authorities. The company is in compliance with all necessary regulations for clinical studies and product development.

Future Prospects

With ongoing advancements in predictive modeling and an increasing emphasis on personalized medicine, POAI is positioned to capitalize on the burgeoning demand for tailored cancer therapies.

How Predictive Oncology Inc. (POAI) Makes Money

Revenue Streams

Predictive Oncology Inc. generates revenue through several key avenues, primarily focused on the application of advanced analytics and personalized medicine.

Clinical Services

The company offers clinical services tailored to oncologists and healthcare providers, utilizing its proprietary data to support treatment decisions and enhance patient outcomes. In 2022, the revenue from clinical services was approximately $4.1 million, a significant increase from the previous year.

Predictive Models

Another substantial revenue generator is the sale of predictive models to pharmaceutical and biotechnology companies. These models assist in drug development and patient stratification. In fiscal year 2022, this segment reported revenues of $3.5 million.

Research and Development Collaborations

POAI has entered into various research and development agreements with academic institutions and industry partners. In 2022, the company recognized $2.0 million in revenue from these collaborations.

Licensing Agreements

Licensing its technology and intellectual property to other companies forms a crucial part of its business model. The company generated $1.6 million in licensing revenue in 2022.

Financial Performance

Predictive Oncology’s financial performance is indicative of its growth trajectory. The latest financial data for the year ended December 31, 2022, is as follows:

Market Strategy

POAI emphasizes a strategic market approach by leveraging its data analytics capabilities in oncology. The company targets:

• Pharmaceutical companies
• Healthcare providers
• Research institutions

Future Growth Prospects

Predictive Oncology aims for growth through several initiatives, including:

• Expanding its clinical services portfolio
• Increasing collaborations with biotech firms
• Enhancing predictive model offerings

Investment and Funding

As of 2022, Predictive Oncology has raised approximately $50 million through various funding rounds aimed at supporting its growth initiatives.

Shareholder Value

The company's stock performance reflects its market position, with a share price of approximately $1.15 as of October 2023. This represents a 15% year-to-date increase in share value.